Patents by Inventor Thomas Kruse Hansen

Thomas Kruse Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 compounds
    Patent number: 9920106
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: March 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Polypeptide protracting tags
    Patent number: 9061067
    Abstract: The invention relates to methods for increasing the plasma half-life of a molecule, such as human growth hormone, comprising covalently linking the molecule to a heterocyclic carboxylic acid bioisostere.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
  • Protracted exendin-4 compounds
    Patent number: 8772232
    Abstract: Novel protracted exendin-4 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: July 8, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen
  • Extended GLP-1 compounds
    Patent number: 8603972
    Abstract: The invention relates to protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: December 10, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dorwald, Lauge Schaffer, Thomas Kruse Hansen
  • Novel GLP-1 Derivatives
    Publication number: 20130244931
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 19, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Niels Langeland Johansen
  • Acylated GLP-1 compounds
    Patent number: 8536122
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Doerwald, Paw Bloch, Thomas Kruse Hansen
  • Amylin derivatives
    Patent number: 8486890
    Abstract: The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: July 16, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Lauge Schäffer, Jesper Lau
  • NOVEL GLP-1 DERIVATIVES
    Publication number: 20130053315
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 28, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG
    Publication number: 20130040884
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 14, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • Acylated GLP-1 Compounds
    Publication number: 20120295847
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dörwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • NOVEL GLP-1 COMPOUNDS
    Publication number: 20120289453
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 15, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Acylated Exendin-4 Compounds
    Publication number: 20120283170
    Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.
    Type: Application
    Filed: May 1, 2012
    Publication date: November 8, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
  • Polypeptide Protracting Tags
    Publication number: 20120088716
    Abstract: Method for increasing half-life of compounds in plasma and novel derivatives of such compounds.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
  • Acylated GLP-1 compounds
    Patent number: 8129343
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: March 6, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Paw Bloch, Thomas Kruse Hansen
  • Protracted Exendin-4 Compounds
    Publication number: 20110301084
    Abstract: Novel protracted exendin-4 compounds and therapeutic uses thereof.
    Type: Application
    Filed: August 18, 2011
    Publication date: December 8, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen
  • Protracted exendin-4 compounds
    Patent number: 8030273
    Abstract: Novel protracted exendin-4 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: October 4, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen
  • Protracted GLP-1 compounds
    Patent number: 7893017
    Abstract: Novel protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: February 22, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen
  • Novel GLP-1 Derivatives
    Publication number: 20100305032
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 5, 2010
    Publication date: December 2, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • NOVEL SALICYLIC ANILIDES
    Publication number: 20100075932
    Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Application
    Filed: November 24, 2009
    Publication date: March 25, 2010
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Preben Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen
  • Salicylic anilides
    Patent number: 7645791
    Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: January 12, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Preben Houlberg Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen